360 Stocks in the S&P 500 Underperformed the Benchmark's 2024 Gain of 24%. Here's 2 High-Yielding S&P 500 Stocks to Buy in 2025, According to Wall Street.

It's been an interesting year for the stock market. The broader benchmark S&P 500 (SNPINDEX: ^GSPC) blazed roughly 24.5% higher (as of Dec. 27), thanks largely to eight high-flying tech stocks with market caps exceeding $1 trillion. Market breadth has not been good this year. The Invesco S&P 500 Equal Weight ETF is only up about 12%.Roughly 360 stocks in the S&P 500 have posted returns below the broader market's average. Of those, 168 stocks are trading in the red this year. This means the market is fairly lopsided right now and there are plenty of opportunities to find good stock bargains if you do your homework. According to Wall Street analysts, there are at least two high-yielding dividend stocks that have trailed the broader market in 2024 but are expected to perform well in 2025.The drugmaker Pfizer (NYSE: PFE) has been struggling with a hangover ever since the COVID-19 pandemic eased and there is now less demand for its vaccines and Paxlovid drug treatment. Shares are down roughly 7.5% this year and 48% since the end of 2022. While markets have outperformed, Pfizer has gone in the opposite direction. However, Pfizer is working hard to take the revenue it earned from its COVID-19 business and develop new drugs in a range of medical conditions, including cancer. Management is forecasting the company may be able to create eight landmark medications by 2030.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool